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Glutathione is the major intracellular redox buffer in the liver and is critical for hepatic detoxiﬁcation of
xenobiotics and other environmental toxins. Hepatic glutathione is also a major systemic store for other
organs and thus impacts on pathologies such as Alzheimer's disease, Sickle Cell Anaemia and chronic
diseases associated with aging. Glutathione levels are determined in part by the availability of cysteine,
generated from homocysteine through the transsulfuration pathway. The partitioning of homocysteine
between remethylation and transsulfuration pathways is known to be subject to redox-dependent reg-
ulation, but the underlying mechanisms are not known. An association between plasma Hcy and a single
nucleotide polymorphismwithin the NADPH oxidase 4 locus led us to investigate the involvement of this
reactive oxygen species- generating enzyme in homocysteine metabolism. Here we demonstrate that
NADPH oxidase 4 ablation in mice results in increased ﬂux of homocysteine through the betaine-de-
pendent remethylation pathway to methionine, catalysed by betaine-homocysteine-methyltransferase
within the liver. As a consequence NADPH oxidase 4-null mice display signiﬁcantly lowered plasma
homocysteine and the ﬂux of homocysteine through the transsulfuration pathway is reduced, resulting in
lower hepatic cysteine and glutathione levels. Mice deﬁcient in NADPH oxidase 4 had markedly increased
susceptibility to acetaminophen-induced hepatic injury which could be corrected by administration of
N-acetyl cysteine. We thus conclude that under physiological conditions, NADPH oxidase 4-derived re-
active oxygen species is a regulator of the partitioning of the metabolic ﬂux of homocysteine, which
impacts upon hepatic cysteine and glutathione levels and thereby upon defence against environmental
toxins.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inc. This is an open access article u
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er).1. Introduction
The term “oxidative stress” has become synonymous with a
plethora of seemingly unrelated pathological conditions. Central to
this concept is the fact that an overproduction of free radicals,
including reactive oxygen and nitrogen species (ROS and RNS)
which are produced in many physiological processes, results in the
damage of macromolecular cell components [31]. Production of
these damaging oxidants is buffered by the maintenance of a
complex array of antioxidant systems, of which the most abundant
is the tripeptide glutathione (γ-glutamylcysteineylglycine; GSH)
redox system [39]. GSH is synthesized within all cells from glycine,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mylcysteine ligase (GCL) and glutathione synthetase (GS), and is
consumed in the detoxiﬁcation of harmful electrophilic metabo-
lites and xenobiotics. Depletion of intracellular GSH is taken as an
indicator of oxidative stress, and is implicated in the pathogenesis
of diverse disease states including Systemic Lupus Erythematosus,
Oedematous Protein Energy Malnutrition, central nervous system
disorders such as Alzheimer's disease, Sickle Cell Anaemia and
chronic diseases associated with aging and infection [39,43].
The most signiﬁcant site of GSH production is the liver [53].
GSH is present at very high concentrations (5–10 mM) in hepa-
tocytes, and is central to the predominant role played by the liver
in the metabolism of xenobiotics. In addition, the liver is the major
exporter of GSH [22] and, as a consequence, a depletion of GSH
within the liver has particularly profound systemic clinical effects
[49].
The intracellular cysteine pool is relatively small and many
studies have demonstrated that it is the limiting amino acid for
GSH synthesis in humans [29], and increasing the supply of cy-
steine prevents GSH deﬁciency under several pathological condi-
tions [28,49]. Cysteine can be imported directly into cells, or is
produced via metabolism of Homocysteine (Hcy).
Hcy is synthesised endogenously from methionine and lies at
the intersection of two metabolic pathways whereby it can be
remethylated to methionine or metabolised to cysteine by trans-
sulfuration (Fig. 1). Approximately 50% of cysteine needed for
hepatic GSH production comes via this transsulfuration pathway
[33], which involves sequential enzymatic activities of cy-
sthathionine β-synthase (CBS) and cystathionine γ-lyase (CGL).
Accordingly, perturbations in this pathway can affect GSH pro-
duction, as illustrated by the phenotype of CBS-null mice in which
GSH levels are severely compromised [51]. Hcy can alternatively be
remethylated to methionine by two pathways. One is folate-de-
pendent and is catalysed by methionine synthase (MS) using
5-methyltetrahydrofolate as the methyl donor [14]. The second
occurs exclusively in liver and (less so) in kidney, and is catalysed
by the enzyme betaine-homocysteine-methyltransferase (BHMT)
using betaine as the methyl donor [14].
Partitioning of Hcy through the transsulfuration and remethyla-
tion metabolic pathways is redox-regulated. Thus the activities of
three of the major Hcy metabolising enzymes; MS, BHMT and CBS,
are regulated by speciﬁc redox-dependent protein modiﬁcationsFig. 1. Schematic representation of Hcy metabolism. Hcy lies at the crossroads of reme
transferase, MAT: methionine-adenosyltransferase, BHMT: betaine-homocysteine-methy
thase, CGL: cystathione-γ-lyase.[23]. Intriguingly, the enzymes involved in remethylation pathways
are inhibited by pro-oxidants whereas the activity of CBS is increased.
Furthermore, in human hepatocytes in vitro there is a linear corre-
lation between the concentration of exogenous oxidant added and
the production of cysteine via transsulfuration [33]. However, the
relevant endogenous oxidant source(s) which mediate this remains
unknown.
Perturbations in Hcy metabolism are reﬂected by altered levels
of circulating plasma Hcy concentrations which correlate with a
diverse range of pathologies including vascular dysfunction, neu-
rodegenerative disorders, congenital defects and diabetes, to-
gether with renal and hepatic syndromes [40]. These variations in
plasma Hyc levels are highly heritable. However, apart from some
rare mutations, the underlying genetic determinants remain un-
known [35]. In a genome-wide association analysis (GWAS), sin-
gle-nucleotide polymorphisms (SNPs) in genes that associate with
plasma Hcy concentration were identiﬁed. In addition to genes
whose functions have already been associated with Hcy metabo-
lism, associations with four novel gene loci were identiﬁed, one of
which was NADPH oxidase 4 (Nox4) [35].
The NADPH oxidase family of enzymes are important gen-
erators of intracellular ROS which modulate redox-dependent
signalling pathways. There are 7 Nox isoforms identiﬁed in
mammals (Nox1–5 and Duox1/2) which show speciﬁcity of cel-
lular distribution, intracellular location, mechanisms of action and
types of ROS produced [4]. Nox4 has been shown to produce
predominantly H2O2 [47], and is widely expressed in many cell
types and adult tissues including kidney, liver, heart and aorta
[24]. Given the known role of redox regulation of Hcy metabolic
pathways and the association of Nox4 with hyperhomocysteine-
mia, a potential regulatory role for Nox4 in Hcy metabolism could
be inferred. To address this, we studied the plasma Hcy levels in a
Nox4-null (Nox4-/-) mouse model. We show that Nox4 ablation
signiﬁcantly promotes the metabolic ﬂux of Hcy along the folate-
independent remethylation pathway resulting in signiﬁcantly de-
creased total plasma Hcy levels. This further impinges on the
transsulfuration pathway leading to signiﬁcantly decreased cy-
steine production and hepatic GSH stores. As a consequence,
Nox4-/- mice display markedly increased susceptibility to acet-
aminophen (APAP, paracetamol)-induced hepatoxicity.thylation and transsulfuration pathways. MS: methionine synthase, MT: methyl-
ltransferase, SAHase: S-adenosylhomocysteine-hydrolase, CBS: cystathione-β-syn-
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Animals-Nox4-/- mice have been described previously [54].
Mice were fed ad libitum on standard chow or folate-deﬁcient/
respective control diets (Harlan, [27]) as described. APAP (200 mg/
kg) and N-acetylcysteine (NAC, 500 mg/kg; both Sigma) were ad-
ministered by oral gavage. For APAP rescue experiments NAC
(10 mg/ml) was additionally added to mouse drinking water
24hours prior to APAP/NAC gavage. Blood was harvested by cardiac
puncture. All experimental procedures were performed following
protocols approved by the ethical committee of King's College
London in accordance with the UK Animals (Scientiﬁc) Procedures
Act of 1986.
2.1. Metabolic Cage Study
8-week-old female mice were fasted overnight and subse-
quently housed in metabolic cages for 6hours, during which time
they were not given food but had free access to water. Urine col-
lected was snap frozen in liquid nitrogen until analysed.
2.2. Western Blot
Protein samples were prepared from homogenised tissue, se-
parated on SDS-PAGE gels, transferred to membranes and probed
with appropriate antibodies as described previously [34]. Anti-
bodies used: β-Actin (Sigma), BHMT (Abcam).
RNA analyses: RNA preparation from cell culture and tissue,
cDNA generation and QPCR were all performed as described pre-
viously [6]. Primer sets used to detect mouse transcripts were as
follows (5’ to 3’): β-actin F: CTGTCGAGTCGCGTCCACCC, R:
ATGCCGGAGCCGTTGTCGAC; MS F: GCAGATGTGGCCAGAAAAG, R:
GCCACAAACCTCTTGACTCC; MTHFR F: GAAGAACATAATGGCGCTG
AG, R: GGCATAGCTGAAGCCTCCTT; BHMT F: GACAAGCTGGAAAA-
CAGAGGA, R: GACAAGCTGGAAAACAGAGGA; choline dehydrogenase
F: TGTCTGGAAGTCCCAGTGC, R: GAAGCAGGACTGCACCATTC;MAT1A
F: CATCGTGCTCGCTCACAAAC, R: CACCAGAGCGCCTCAGATC; MAT2A
F: TTACGCCCAGATTCTAAAACTCAA, R: GCACAGCACCCCGATCTT;
MAT2B F: CTGCTTCCCAGCTGAATGTG, R: TCGCAGCTGCCTC-
CTTTG. Primers used to detect human transcripts were:
β-actin F: GCGAGAAGATGACCGAGATCA, R: TCACCGGAGTCCATCAC-
GAT, choline dehydrogenase F: GTGCACCGTATCCTGTCACT, R:
TCTGATCCACGGAGGGGAAT, BHMT F: TCACCTTCTATGCGAGTGAAGA,
R: CAAGCAGCTTCATTGACTTCC.
2.3. Glutathione Measurements on liver tissue
Freshly isolated liver tissue was snap-frozen in liquid N2, and
stored at  80 °C until analysed. Samples were homogenised in
phosphate-buffered saline containing 2 mM EDTA, at a con-
centration of 25 mg tissue/ml PBS, and subsequently diluted 1/10
in PBS/EDTA for analyses. GSH assays were performed using the
GSH-Glo assay kit (Promega), according to manufacturer's re-
commendations with modiﬁcations as described previously [6]. To
measure total GSH levels (GSHþGSSG) extracts (50 ml) were pre-
incubated in a ﬁxed concentration of 1 mM Tris(2-carbox-
yethylphosphine hydrochloride (TCEP; Sigma) for 30minutes at
room temperature. From measurements of total and reduced GSH
the level of oxidized GSSG, and the glutathione redox couple (GSH:
GSSG) were calculated. It should be noted that this method typi-
cally results in higher levels of total GSH than described elsewhere
in the literature, and as a consequence the GSH:GSSG ratios are
routinely lower than described by others. We believe this to be
due to the very strong reducing power of the TCEP, and as its effect
is consistent across all samples, it in no way invalidates the relative
values presented here.2.4. Methionine and Cysteine Measurements in Liver samples
For methionine measurements liver tissue was homogenised in
ice-cold 5% percholoric acid, centrifuged and the supernatant
(extract) collected. Methionine was measured in extracts from Wt
and Nox4-/- mouse livers using a Bridge-Its L-Methionine (L-Met)
Fluorescence Assay (mediomics) as per the manufacturer's proto-
col. Cysteine content was determined using a previously described
method [16].
ALT and AST Activity Measurements-Plasma samples were
analysed using an ADVIA 2400 Chemistry System (Siemens
Healthcare Diagnostics.
Homocysteine Measurements-Hcy concentrations were de-
termined in plasma and urine using the ADVIA Centaur CP Im-
munoassay System (Siemens Healthcare Diagnostics Ltd.).
2.6. Histology and Assessment of Liver Injury
Sections of the right medial lobe of the liver were harvested
and ﬁxed in 4% paraformaldehyde for 4hours at 4 °C. Sections were
dehydrated stepwise in graded concentrations of ethanol and
embedded in parafﬁn. 6 μm sections were stained with haema-
toxylin and eosin (H&E) for light microscopic examination using
an Olympus BH51 microscope. Pictures were taken using an
Olympus DP26 digital camera. Sections were reviewed and graded
by a liver histopathologist (AQ) blind to genotype and treatment
conditions. An initial review of the sections identiﬁed three sig-
niﬁcant features of histological injury; hepatocellular ballooning,
presence of sinusoidal congestion, and conﬂuent hepatocellular
necrosis. After careful search at 200x or 400x magniﬁcation sec-
tions were subsequently graded as follows: none visible: No ab-
normalities apparent in liver sections, grade 1: no necrosis, mini-
mal sinusoidal congestion with some hepatocellular ballooning
present, grade 2: no necrosis, moderate sinusoidal congestion and
hepatocellular ballooning, grade 3: focal necrosis limited to the
area immediately around the centrilobular vein, moderate sinu-
soidal congestion and hepatocellular ballooning, grade 4: marked
necrosis around the centrilobular vein and extending into the
midzonal cell region (coagulative-type hepatocellular necrosis)
presenting as a diffuse change, immediately evident at low power
magniﬁcation, and affecting more than one third of the lobular
area), panlobular congestion and signiﬁcant hepatocellular
ballooning.
2.7. Measurement of Hepatic Betaine and Dimethylglycine
Liver samples or HepG2 cells were harvested, snap frozen and
stored until analysed. Tissue samples and cells were homogenised
in acetonitrile containing 0.1% formic acid (185 μl/20 mg tissue).
100 μl of extract was evaporated to dryness and resuspended in a
solution of 0.1% pentaﬂuorooctanoic acid, 0.1% formic acid in 0.5%
acetonitrile in water containing 50 ng/ml of Pemoline as an in-
ternal standard and vortexed to mix. Samples were analysed on a
Thermo Accela LC system interfaced directly to Thermo LTQ XL
linear ion trap mass spectrometer.
2.8. Immunocytochemistry
HepG2 cells were cultured on cover slips, before ﬁxation (4%
paraformaldehyde, 15minutes) and permeabilisation (0.1% triton
X-100 in PBS, 20minutes). After blocking (3% BSA, 1.5% normal goat
serum in PBS), cells were incubated with primary antibodies
against BHMT (mouse monoclonal, ab52144, AbCam, 1:500 dilu-
tion) and Nox4 (rabbit polyclonal; 1:200 dilution [1]. Antibody
bindings were visualised using Alexa 568-conjugated anti-mouse
IgG and 488-conjugated anti-rabbit IgG secondary antibodies
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sualised using a Leica scanning confocal microscope (TCS-SP5).
Red and green ﬂuorescent signals were detected using appropriate
ﬁlter sets (excitation 568/emission 620 nm or 488/emission 505–
530 nm respectively). Confocal images were acquired as transcel-
lular 0.4 μm sections in the Z plane (15 scans/plane).
2.9. Quantatative Analyses of Co-localisation
Co-localisation of BHMT and Nox4 staining was quantiﬁed
using the ImageJ: Coloc2 plugin (National Institutes of Health), in
order to calculate the Pearson's correlation coefﬁcient, which gives
a measure of the correlation between the intensity distributions of
the red (BHMT) and green (Nox4) channels. 5 independent, un-
saturated images were used for the analysis.
2.10. Glutathione assays on HepG2 cells
HepG2 cells were seeded (104 cells/well) on a 96-well cell
culture plate that had been coated with a 1% gelatin solution. Cells
were transduced with an adenovirus vector encoding either Nox4
(AdNox4) or β-galactosidase (AdβGal) as control at an MOI of 20.
Cells were incubated for 24 h and GSH assays were performed
using the GSH-Glo assay kit (Promega), according to manufac-
turer's recommendations.
2.11. Measurement of ROS
Catalase-Inhibitable extracellular ROS, generated by HepG2
cells (transduced with AdNox4/AdβGal, as above) cells was mea-
sured using a homovanillic acid- (HVA-)based assay, as described
previously [2].
2.12. BIAM-labeling
Labeling of BHMT protein was carried out essentially as
described previously [42]. All buffers were deoxygenated by bub-
bling with argon gas for at least 30 mins. 300 ng of puriﬁed BHMT
(Abcam) or BSA (Sigma) were used per reaction, in labelling buffer
(100 mM phosphate buffer, pH 6.0, 50 mM NaCl, 1 mM EDTA, 1 mM
EGTA). Protein was treated with H2O2 for 20mins with concentra-
tions as indicated, or with 20 mM N-ethyl-maleimide (NEM;
Sigma), before incubation with 10 μM N-(biotinoyl)-N'-(iodoacetyl)
ethylenediamine (BIAM; Life Technologies) at 37 °C for 30 mins. The
labeling reaction was stopped by the addition of 20 mM DTT (ﬁnal
concentration). BIAM-labeled proteins were afﬁnity puriﬁed on
magnetic streptavidin-coated beads (Dyna beads) and analysed by
immunoblotting.
For direct labelling of BHMT in HepG2 cells (transduced with
AdNox4/AdβGal, as above), the ‘BIAM Switch’ method [8] was
used. Brieﬂy, HepG2 cells were incubated with 20 mM NEM,
30 mins, at 37 C. Cells were then washed with ice cold PBS to re-
move excess NEM. Cells were lysed in labelling buffer containing
0.5% NP-40 and protein was quantitated by Bradford assy. 300 ug
total protein was used per sample. Oxidised residues were reduced
by the addition of DTT to a ﬁnal concentration of 3 mM. Excess
DTT was removed using Zeba™ Spin Desalting Columns, 7 K
MWCO (Thermo, cat. No. 89882) and then labelled with 10uM
BIAM, 37 C, 30mins. The reaction was stopped by the addition of
20 mM DTT. BIAM labelled proteins were afﬁnity puriﬁed on
magnetic streptavidin-coated beads (Dyna beads). Labelled pro-
teins were analysed by immunoblot.
Statistics-Data are expressed as mean7S.E. Comparisons be-
tween sample groups or measurements at different time points
were made by unpaired Student's t test.3. Results
3.1. Nox4 deﬁciency decreases plasma levels of Hcy
We investigated the effect of Nox4 deﬁciency on plasma Hcy
concentrations. 8-week-old female wild-type (Wt) and Nox4-/-
mice were fed a normal chow diet ad libitum or were fasted
overnight after which total plasma Hcy concentrations were de-
termined. Feeding/fasting had no signiﬁcant effect on baseline
plasma Hcy levels (Fig. 2A). However, a highly signiﬁcant reduction
in plasma Hcy concentration was observed in Nox4-/- mice com-
pared to Wt mice, irrespective of feeding status (Fig. 2A). A similar
result was obtained using cohorts of 8-week-old (fasted) male
mice (Fig. 2A), indicating that the effect of Nox4 ablation on
plasma Hcy concentrations is not sex-dependent. Since baseline
concentrations of Hcy differ between male and female mice in
general [51], all subsequent experiments were performed on fe-
male mice for consistency.
Altered renal function has been associated with altered plasma
Hcy levels [15]. Since Nox4 is highly expressed in the kidney [17],
renal Hcy clearance was determined. Urine production, and crea-
tinine excretion and clearance rates were similar in both sets of
animals (Fig. 2B,C&D.). Excretion rates of Hcy were signiﬁcantly
lower in the Nox4-/- cohort (as expected due to the lower plasma
Hcy concentrations; Fig. 2E), however there were no differences
in Hcy clearance rates between the two groups (Fig. 2F). Thus
renal function of Nox4-/- animals is comparable to that of Wt
controls.
3.2. Cysteine and GSH levels are reduced in Nox4-/- mouse livers
Cysteine is generated from Hcy, predominantly in the liver, via
the transsulfuration pathway (Fig. 3A) and its bioavailability cri-
tically affects levels of hepatic GSH [46]. Therefore we measured
hepatic cysteine and GSH levels and found that cysteine levels,
GSH levels and the GSH/GSSG ratio were all signiﬁcantly reduced
in Nox4-/- liver samples (Fig. 3B,C&D).
To determine whether the lower GSH levels were due to the
reduced hepatic cysteine levels, mice were injected with either
vehicle or 500 mg/kg of N-acetyl cysteine (NAC) for 4hours before
livers were harvested. NAC treatment restored GSH levels (Fig. 3E)
and normalised the GSH:GSSG ratio of Nox4-/- mice to that of Wt
control animals (Fig. 3F). We therefore propose that lower bioa-
vailability of cysteine due to reduced Hcy ﬂux through the trans-
sulfuration pathway is the underlying cause of the low hepatic
GSH levels in the Nox4-/- mice.
3.3. Nox4-/- animals are more susceptible to liver damage in a model
of acetaminophen (APAP)-induced hepatotoxicity
Decreased antioxidant capacity has been linked to increased
susceptibility to hepatotoxic agents. Therefore we tested whether
the Nox4-/- mice were more susceptible to APAP-induced hepato-
toxicity. Wt and Nox4-/- mice were fasted overnight and subse-
quently administered either vehicle or a moderate dose of APAP
(200 mg/kg, oral gavage) which was shown previously not to in-
duce signiﬁcant mortality (o10%) within a 24 h period [44]. After
24hours mice were sacriﬁced and the activities of the liver en-
zymes alanine-transaminase (ALT) and aspartate-transaminase
(AST) in blood plasma were determined. Baseline activity levels
were equivalent in the two groups, and Wt APAP-treated animals
showed no signiﬁcant change in these enzymatic activity levels
compared to vehicle-treated controls. However, Nox4-/- animals
exhibited highly signiﬁcant and strikingly increased AST and ALT
activity levels upon APAP treatment, consistent with substantial
liver damage (Fig. 4A&B).
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normal histology with no signs of damage at baseline (Fig. 4C),
while those from Wt mice treated with APAP presented with only
mild histological signs of injury. Thus they displayed some sinu-
soidal congestion and hepatocellular ballooning (arrowed in
Fig. 4D&F (Wt)) but without conﬂuent necrosis in centrilobular
and perivenular areas. By contrast, and consistent with the sig-
niﬁcantly elevated activity levels of AST and ALT, Nox4-/- mice
treated with APAP exhibited severe liver damage. In these animals,
areas of conﬂuent necrosis were apparent in a pattern typical of
APAP overdosage [37] that was accompanied by pronounced si-
nusoidal congestion and signiﬁcant hepatocyte ballooning injury
(arrowed in Fig. 4D&F (Nox4-/-)). Apoptosis has been shown to
occur after APAP overdose [37], and accordingly substantially more
apoptotic bodies were observed in liver sections from Nox4-/- mice
which were primarily associated with areas of frank necrosis. Co-
administration of NAC (both 10 mg/ml from previous 24hours in
drinking water, together with 500 mg/kg by oral gavage) with
APAP to both Wt and Nox4-/- mice remarkably reversed most of the
damage associated with APAP treatment in both groups as evi-
denced by decreased ALT and AST activity levels (Fig. 4A&B), and by
the inhibition of hepatocellular injury markers. Most notably, NAC
treatment completely protected against hepatocellular necrosis
in Nox4-/- animals (Fig. 4E). Thus ablation of Nox4 renders micesigniﬁcantly more susceptible to APAP-induced hepatotoxicity, pri-
marily due to reduced hepatic cysteine, and hence decreased GSH
levels. These results are summarized in Table 1.
3.4. Folate-dependent remethylation is not compromised in
Nox4 -/-mice
Our data suggest that lower Hcy levels in Nox4-/- mice impact
upon the ﬂux of Hcy to cysteine, resulting in reduced GSH levels
and increased susceptibility to hepatotoxic agents. As Nox4 is
known to be an important generator of physiological levels of ROS,
we sought to identify redox-dependent mechanism(s) which
might underlie this reduction in Hcy levels. The remethylation of
Hcy to methionine by both folate-dependent and –independent
mechanisms is known to be inhibited by oxidation [23], thus Nox4
ablation might potentially increase the activity of either or both of
these pathways. The folate-dependent remethylation pathway,
catalysed by MS (Fig. 5A), can be inhibited by dietary folate de-
privation, resulting in increased plasma Hcy levels [7]. Wt and
Nox4-/- mice were therefore fed a folate-deﬁcient diet. As ex-
pected, Wt plasma Hcy levels increased signiﬁcantly within 2 days
of folate deprivation and remained signiﬁcantly higher at 2 weeks
(Fig. 5B). By contrast, plasma Hcy levels of the Nox4-/- mice did not
increase with folate deprivation at either time-point (Fig. 5B). Thus
Fig. 4. Nox4-/-animals are more susceptible to liver damage in a model of acetaminophen-induced hepatotoxicity.Wt and Nox4-/- (n¼5 in each group) mice were fasted overnight,
followed by administration of either water (control), acetaminophen (APAP; 200 mg/kg) or APAPþNAC (200 mg/kg and 500 mg/kg respectively). After 24hours mice were
sacriﬁced and plasma and tissue samples were harvested. A & B, Aminotransferase activity assays of ALT and AST activity respectively in plasma fromWt and Nox4-/- animals
after treatments as indicated. IU/L: standard international units per litre. C, D, and E: H & E stained histological sections of liver fromWt and Nox4-/- mice after treatments as
indicated Scale bar: 70 μm. F, Higher magniﬁcation images of sections shown in D. Scale bar 17 μm. All data are presented as mean þ/-S.E.M. nn: p¼o0.01. n.s.: not
signiﬁcant. (Arrows depict areas of hepatocellular ballooning, sinusoidal congestion and necrosis.).
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Table 1
Grading of liver injury after APAP treatment: Animals received 300 mg APAP/kg.
NAC was administered at 500 mg/kg. The degree of ballooning, necrosis and con-
gestion were graded according to the criteria outlined in materials and methods.
n¼5 per group. Highly signiﬁcant changes in all criteria were observed in the
Nox4-/- cohort, compared to all other groupsnn: p¼o0.01 vs Wt. Data presented as
Mean7SEM.
Hepatocellular
Ballooning
Conﬂuent
Necrosis
Congestion
Wt Saline none visible none visible none visible
Nox4-/- Saline none visible none visible none visible
Wt APAP 2.070.20 0.7570.02 0.3570.15
Nox4-/- APAP 2.670.30nn 3.7570.09nn 1.070.19nn
Wt APAP NAC 0.2570.06 none visible none visible
Nox4-/- APAP
NAC
0.6070.03 none visible none visible
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increased ﬂux through the folate-dependent remethylation path-
way since inhibition of this pathway served only to increase the
difference in plasma Hcy levels between Wt and Nox4-/- mice.
3.5. Nox4 ablation increases hepatic betaine homocysteine methyl-
transferase (BHMT)-catalysed remethylation
The folate independent remethylation of Hcy to methionine,
catalysed by BHMT, uses betaine as the methyl donor (Fig. 6A).
Betaine is exclusively and irreversibly catabolised by BHMT to
generate dimethylglycine (DMG) [36], and the ratio of the hepatic
concentration of betaine:DMG can be taken as a measure of the
activity of this pathway [13,21,32]. We therefore determined the
concentrations of BHMT and DMG in liver samples from Wt and
Nox4-/- mice by mass spectrometry. Liver betaine concentrations
were signiﬁcantly lower in the Nox4-/- mouse cohort (Fig. 6B)
while their DMG levels were similar to those of livers from Wt
mice (Fig. 6C). We calculated the ratio of DMG:betaine and de-
monstrated a highly signiﬁcant decrease in this ratio in the Nox4-/-
mice, indicative of increased BHMT-mediated remethylation
(Fig. 6D). Hepatic BHMT mRNA (Fig. 6E) and protein (Fig. 6F) ex-
pression levels were unchanged between Wt and Nox4-/- mice.
These data are therefore consistent with a redox-mediated in-
crease in BHMT metabolic activity, resulting from Nox4 ablation,
acting to lower both liver betaine levels and plasma levels of Hcy.
Changes in betaine bioavailablity have been suggested to be
linked causally to changes in choline dehydrogenase (CDH; whichm
ol
/L
)
Fig. 5. Lower plasma Hcy levels were not due to increased folate-dependent remethylation.
remethylation pathways. (MAT: methionine adenosyltransferase, MT: methyl transferas
methyltetrahydrofolate reductase). B, Plasma Hcy concentrations from Wt and Nox4-/- m
are presented as mean þ/-S.E.M. nn: p¼o0.01. n: p¼o 0.05. n.s.: not signiﬁcant.catalyses betaine biosynthesis) mRNA expression [12]. Perhaps
consistent with this, mRNA levels of CDH were signiﬁcantly in-
creased in Nox4-/- liver samples (Fig. 6G). However protein levels
of CDH were not determined in this previous study, and we were
unable to determine any difference between CDH protein ex-
pression in Nox4-/- and wt livers (data not shown). The sig-
niﬁcance of these observations therefore remains unclear.
3.6. The Nox4-dependent regulation of BHMT activity is a conserved
mechanism in human HepG2 cells
To investigate further the mechanism of Nox4-dependent reg-
ulation of BHMT in vitro, we utilised the HepG2 human hepatocyte
cell line. We immunostained HepG2 cells for Nox4 and BHMT.
Consistent with previous observations we saw strong Nox4 ex-
pression in the nucleus [1], in addition to diffuse extra-nuclear
expression, while BHMT expression was predominantly extra-nu-
clear (Fig. 7F). Pearson correlation coefﬁcient analysis demon-
strated a negative correlation of Nox4 and BHMT within the nu-
clear compartment, but signiﬁcant co-localisation outside of the
nucleus (Fig. 7F). Adenoviral-mediated overexpression of Nox4 in
HepG2 cells resulted in signiﬁcantly higher intracellular levels of
betaine (Fig. 7A) and GSH (Fig. 7B), consistent with redox-de-
pendent inhibition of BHMT, and complementary to our in vivo
observations. The mRNA and protein levels of BHMT were un-
changed by Nox4 overexpression (Fig. 7C & D); again consistent
with a post-translational redox-dependent regulatory mechanism.
There was also a statistically signiﬁcant, albeit small, decrease in
CDH mRNA levels upon Nox4 overexpression, again complimen-
tary to our in vivo observations (Fig. 7E).
Crystal structure analyses of BHMT have demonstrated a potential
structural basis for a functional switch in BHMT activity, dependent
upon the oxidation of critical cysteine residues which co-ordinate a
zinc ion within its active site [10]. We sought to determine whether
BHMT is a bona ﬁde target of H2O2-mediated oxidation. Recombinant
BHMT was incubated with increasing concentrations of H2O2 and its
oxidation status was assessed using N-(biotinoyl)-N'-(iodoacetyl)
ethylenediamine (BIAM), which irreversibly alkylates reduced thiol
(S-H) groups. Thus a reduction in BIAM incorporation reﬂects an
increase in unlabelled cysteine residues which are susceptible to
H2O2-mediated oxidation. Western blot analyses revealed a dose-de-
pendent susceptibility of BHMT to H2O2-induced oxidation at phy-
siological concentrations (o 20 μM) [9]. By contrast, under equivalent
experimental conditions, BSA was oxidised only at relatively high
(non-physiological) concentrations of H2O2 (4100 μM) (Fig. 8A&B).Control 2d 2wk
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Fig. 6. Nox4 ablation increased hepatic betaine homocysteine methyltransferase (BHMT)-catalysed remethylation.A, Schematic representation of the endogenous folate-
independent remethylation pathway (BHMT: betaine homocysteine methyltransferase). B,C,D Quantiﬁcation of mass spectrometry analyses of extracts from 8 week old
female Wt and Nox4-/- liver samples to determine concentrations of betaine (B) dimethylglycine (DMG; C) and ratio of betaine: DMG (D; n¼3 in each case). E, Q-PCR
analysis of BHMT mRNA expression in 8 week old female Wt and Nox4-/- liver samples, relative to levels of β-actin (n¼5). F, Representative immunoblot and
quantitative histogram indicating BHMT protein expression levels in liver samples from 8 week old female Wt and Nox4-/- mice (n¼3). G, Q-PCR analysis of choline
dehydrogenase mRNA expression levels in liver samples from 8 week old female Wt and Nox4-/- mice relative to levels of β-actin (n¼3). All data are presented as mean
þ/-S.E.M. nn: p¼o0.01. n: p¼o 0.05. n.s.: not signiﬁcant.
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overexpression of Nox4 in HepG2 cells resulted in a signiﬁcant
increase in catalase-inhibitable extracellular H2O2 (Fig. 8C), con-
sistent with our previous studies in HEK293 cells and HUVECs
[2,38]. Therefore, to test whether Nox4 overexpression, per se,
induced BHMT oxidation, a direct, “biotin-switch” labelling strat-
egy was employed [8]. As shown (Fig. 8D), Nox4 overexpression in
HepG2 cells induced a highly signiﬁcant increase in labelled (and
hence oxidised) BHMT, consistent with the increased susceptibility
of the recombinant protein to H2O2-induced oxidation, described
above. Therefore, taken together, these results suggest that BHMT
activity can potentially be regulated by direct redox-regulation of
critical cysteine residues via Nox4-generated H2O2.
4. Discussion
Here we report that the total plasma concentrations of Hcy in
Nox4-/- mice are profoundly reduced irrespective of sex or nutritionalstatus. In addition our data clearly demonstrate that the lower basal
levels of plasma Hcy result in reduced metabolic ﬂux to cysteine, and
consequently lower hepatic GSH levels. This is of signiﬁcant clinical
importance, since depleted GSH stores have far-reaching implications
for disease susceptibility and progression, as exempliﬁed by the
strikingly increased sensitivity of Nox4-/- mice to APAP-induced he-
potoxicity that we observe here.
Although Nox4 is highly expressed within the kidney [17], we
found no evidence that altered renal Hcy clearance in the Nox4-/-
mice accounts for the lowered plasma Hcy levels,consistent with a
previous study, which found no detectable kidney dysfunction at
baseline in Nox4-/- mice [3]. We therefore conclude that the hy-
pohomocystenemia observed in Nox4-/- mice was due to the
dysregulation of systemic Hcy metabolism.
Hcy is predominantly metabolised in the liver [46]. Our data
strongly support the premise that the ﬂux of Hcy through the
remethylation or transsulfuration pathways is under redox-
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Fig. 7. Nox4 overexpression increases betaine and GSH levels in HepG2 cells in vitro.A, Betaine levels and B, GSH levels in HepG2 cells transduced with AdNox4 or control, AdβGal
(n¼6). C, mRNA levels of BHMT, normalised to βactin in HepG2 cells transduced with AdNox4 or control, AdβGal (n¼3).D, Western blot analysis of BHMT protein levels in HepG2
cells transduced with AdNox4 or control AdβGal. E, mRNA levels of CDH, normalised to βactin in HepG2 cells transduced with AdNox4 or control, AdβGal (n¼3). F, Representative
confocal microscopy images of HepG2 stained with DAPI (blue), Nox4(green) and BHMT(red) and histograms showing Pearson's coefﬁcients calculated for co-localization of Nox4
and BHMT in nuclear and extra-nuclear cellular compartments. The coefﬁcient can vary between -1 and þ1, with negative values representing inverse correlations, zero re-
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Fig. 8. BHMT is a potential direct oxidative-target of Nox4-generated ROS.A, Representative immunoblot showing decreasing labelling of BHMT after BIAM labelling of
H2O2-oxidised puriﬁed recombinant BHMT and BSA. B, Graph of the densitometric analysis of labelled BHMT band intensities under the indicated H2O2 concentrations. R2
values indicate that there is a good correlation between the decreases in BHMT labelling and increasing H2O2 concentration (i.e. increasingly oxidised BHMT), while there
is a poor correlation between BSA labelling at the same H2O2 concentrations. C, Extracellular catalase-inhibitable H2O2 generated by HepG2 cells transduced with
AdNox4 or control, AdβGal (n¼3). D, Western blot and densitometric quanriﬁcation of BIAM-switch labelled (ie oxidised) BHMT levels in HepG2 cells transduced with
AdNox4 or control, AdβGal (n¼3). Equivalent amounts (20μg) of “input” protein were blotted for βactin, to serve as a control. Above data are represented as mean þ/-S.E.
M. n: p¼o 0.05. n.s.: not signiﬁcant.
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fector of this regulation. Remethylation pathways are potentially
inhibited in vivo by pro-oxidants, due to known redox modiﬁca-
tions of critical enzymes [23]. Consistent with this, we found
evidence for increased activity of BHMT in the (less ROS-produ-
cing) Nox4-/- mice. Thus betaine levels, together with the ratio of
betaine:DMG were both signiﬁcantly reduced in the livers of
Nox4-/- mice, indicating increased BHMT activity. Experiments in a
human hepatocyte cell line (HepG2) complement these in vivo
ﬁndings: Nox4 overexpression in HepG2 cells acted to increase the
baseline intracellular concentrations of both betaine and GSH,
consistent with reduced BHMT activity. These experiments further
suggest that redox-regulation of BHMT activity may represent a
conserved mechanism among mammalian species to direct Hcy
partitioning to either methionine or cysteine pools.
We hypothesise that the regulation of BHMT by Nox4 is likely
to be based on the ‘redox switch' mechanism proposed by its
crystal structure. Under reducing (activating) conditions a catalytic
zinc ion is coordinated at the active site of BHMT by three cy-
steines (Cys 217, 299, 300). Oxidation promotes an intramolecular
disulphide bond between Cys217 and Cys299 resulting in the
displacement of the zinc ion, and enzyme inactivation [10]. Asimilar mechanism by which Nox4-generated ROS inhibits the
activity of protein-tyrosine-phosphatase 1B through the oxidation
of critical active site cysteines has also been described [11,50],
suggesting a conserved mechanism for redox-mediated enzyme
inactivation. Consistent with this, we demonstrate here that H2O2
(the product of Nox4) is able to oxidise thiol groups of puriﬁed
BHMT in a dose-dependent manner at physiological concentra-
tions, while overexpression of Nox4 in HepG2 cells resulted in
both increased H2O2 production, and clear oxidation of BHMT.
Furthermore, analyses in HepG2 cells demonstrated that Nox4 and
BHMT co-localise within non-nuclear compartment(s) potentially
to enable direct redox-regulation of BHMT by Nox4-generated
H2O2.
We thus propose that under normal physiological conditions
in vivo, ROS generated by Nox4 acts as a negative regulator of
BHMT activity. Hence ablation of Nox4 results in hyperactivation of
BHMT and a higher rate of Hcy ﬂux through this remethylation
pathway, resulting in lower plasma Hcy levels and a reduced
metabolic ﬂux to cysteine. The potential clinical signiﬁcance of
misregulated BHMT is becoming increasingly clear. Deletion of
BHMT in mice, which results in greatly increased plasma Hcy and
hepatic betaine, renders these animals susceptible to fatty liver
T.V.A. Murray et al. / Free Radical Biology and Medicine 89 (2015) 918–930 929and hepatocellular carcinomas [48]. By contrast the Zucker Dia-
betic Fatty rat model of type 2 diabetes is characterised, at early
stages, by increased levels of expression of BHMT that correlate
with signiﬁcantly reduced levels of hepatic betaine and plasma
homocysteine [52].
As a consequence of lowered hepatic cysteine levels, Nox4-/-
mice display impaired hepatic GSH production. GSH is the most
important and most abundant cellular redox buffer, and conse-
quently depletion of GSH stores has been shown to render cells
more susceptible to an oxidant insult. Hepatic GSH insufﬁciency in
Nox4-/- mice leads to a markedly increased susceptibility to APAP-
induced liver toxicity. APAP is metabolised by the cytochrome
P450 enzymes to the highly reactive compound N-acetly-p-ben-
zoquinone imine (NAPQI). One of the primary mechanisms of
detoxifying NAPQI is through the production of an APAP-GSH
conjugate [18]. The ingestion of large doses of APAP therefore
leads to a substantial depletion of hepatic GSH, and clinical
treatment of APAP-induced liver damage is administration of a
large dose of NAC to help restore GSH levels [20]. The increased
APAP-induced liver damage in the Nox4-/- mice was fully rescued
by oral administration of NAC as a source of cysteine, conﬁrming
that the reduced production of cysteine (and as a consequence, of
GSH) in these mice was the cause of the phenotype. Lower base-
line hepatic GSH levels are also likely to render these mice more
susceptible to other hepatotoxic stimuli (in addition to APAP), as
well as to diseases in which lower GSH levels are known to be
causative of disease progression. For example non-alcohol fatty
liver disease, ﬁbrosis, hepatocellular carcinoma, hepatitis and cir-
rhosis have all been linked with decreased antioxidant capacity
[5]. In addition, hepatic GSH represents the major systemic store
which can be mobilised as required to supply other physiological
systems [25]. Low systemic GSH levels have also been implicated
in a wide array of pathologies such as cardiovascular diseases [26],
neurodegenerative diseases[30], diabetes [41], and cancer [45], in
addition to developmental disorders such as congenital heart de-
fects [19].
It may, however, seem counter-intuitive for the relative levels
of reduced GSH levels to decrease in the absence of an oxidant
(Nox4) as described here. Moreover in a previous study, in which
Nox4 was ectopically overexpressed in cardiomyocytes, we in-
triguingly observed a converse increase in reduced GSH within the
heart. In that case the cardiac-speciﬁc overexpression of Nox4 was
demonstrated to upregulate the Nrf2 antioxidant response, which
in turn promoted the expression of the GSH biosynthetic and re-
cycling enzymes [6]. We found no evidence for the involvement of
Nrf2 in the Nox4-dependent phenotype described here (thus
Nrf2-/- mice did not display altered hepatic GSH levels; data not
shown). None-the-less, both these experiments highlight the
danger in the assumption that increased oxidant expression will
necessarily result in a more oxidised cellular redox state, as is
often made.
In conclusion, we demonstrate a physiological role of Nox4 in
regulating the partitioning of Hcy ﬂux to the remethylation and
transsulfuration pathways by the redox-dependent regulation of
BHMT activity. As a consequence of Nox4 deﬁciency, hepatic GSH
stores become depleted, with clear profound clinical implications
for both hepatic and systemic health.Acknowledgements
This work was supported by grants from the British Heart Foun-
dation (BHF), nos. PG/11/124/29318 and RG/08/110/25922, a BHF
Centre of Excellence Award-RE/13/2/30182 and a Foundation Leducq
Transatlantic Network of Excellence Award grant no. 09CVD01.References
[1] N. Anilkumar, G. San Jose, I. Sawyer, C.X. Santos, C. Sand, A.C. Brewer,
D. Warren, A.M. Shah, A 28-kDa splice variant of NADPH oxidase-4 is nuclear-
localized and involved in redox signaling in vascular cells, Arteriosclerosis,
thrombosis, and vascular biology 33 (2013) e104–e112.
[2] N. Anilkumar, R. Weber, M. Zhang, A. Brewer, A.M. Shah, Nox4 and nox2
NADPH oxidases mediate distinct cellular redox signaling responses to agonist
stimulation, Arteriosclerosis, thrombosis, and vascular biology 28 (2008)
1347–1354.
[3] A. Babelova, D. Avaniadi, O. Jung, C. Fork, J. Beckmann, J. Kosowski,
N. Weissmann, N. Anilkumar, A.M. Shah, L. Schaefer, et al., Role of Nox4 in
murine models of kidney disease, Free radical biology & medicine 53 (2012)
842–853.
[4] K. Bedard, K.H. Krause, The NOX family of ROS-generating NADPH oxidases:
physiology and pathophysiology, Physiological reviews 87 (2007) 245–313.
[5] F. Bellanti, J. Sastre, G. Serviddio, Reactive Oxygen Species (ROS) and Liver
Disease Therapy, in: I. Laher (Ed.), In Systems Biology of Free Radicals and
Antioxidants, Springer, Berlin Heidelberg, 2014, pp. 1809–1838.
[6] A.C. Brewer, T.V. Murray, M. Arno, M. Zhang, N.P. Anilkumar, G.E. Mann, A.
M. Shah, Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo,
Free radical biology & medicine 51 (2011) 205–215.
[7] J.M. Burgoon, J. Selhub, M. Nadeau, T.W. Sadler, Investigation of the effects of
folate deﬁciency on embryonic development through the establishment of a
folate deﬁcient mouse model, Teratology 65 (2002) 219–227.
[8] J.R. Burgoyne, P. Eaton, A rapid approach for the detection, quantiﬁcation, and
discovery of novel sulfenic acid or S-nitrosothiol modiﬁed proteins using a
biotin-switch method, Methods in enzymology 473 (2010) 281–303.
[9] J.R. Burgoyne, S. Oka, N. Ale-Agha, P. Eaton, Hydrogen peroxide sensing and
signaling by protein kinases in the cardiovascular system, Antioxidants & re-
dox signaling 18 (2013) 1042–1052.
[10] C. Castro, N.S. Millian, T.A. Garrow, Liver betaine-homocysteine S-methyl-
transferase activity undergoes a redox switch at the active site zinc, Archives
of biochemistry and biophysics 472 (2008) 26–33.
[11] K. Chen, M.T. Kirber, H. Xiao, Y. Yang, J.F. Keaney Jr., Regulation of ROS signal
transduction by NADPH oxidase 4 localization, The Journal of cell biology 181
(2008) 1129–1139.
[12] T.W. Chew, X. Jiang, J. Yan, W. Wang, A.L. Lusa, B.J. Carrier, A.A. West, O.
V. Malysheva, J.T. Brenna, J.F. Gregory 3rd, et al., Folate intake, MTHFR geno-
type, and sex modulate choline metabolism in mice, The Journal of nutrition
141 (2011) 1475–1481.
[13] S. Fernandez-Roig, P. Cavalle-Busquets, J.D. Fernandez-Ballart, M. Ballesteros,
M.I. Berrocal-Zaragoza, J. Salat-Batlle, P.M. Ueland, M.M. Murphy, Low folate
status enhances pregnancy changes in plasma betaine and dimethylglycine
concentrations and the association between betaine and homocysteine, The
American journal of clinical nutrition 97 (2013) 1252–1259.
[14] J.D. Finkelstein, Methionine metabolism in mammals, The Journal of nutri-
tional biochemistry 1 (1990) 228–237.
[15] A.N. Friedman, A.G. Bostom, J. Selhub, A.S. Levey, I.H. Rosenberg, The kidney
and homocysteine metabolism, Journal of the American Society of Ne-
phrology: JASN 12 (2001) 2181–2189.
[16] M.K. Gaitonde, A spectrophotometric method for the direct determination of
cysteine in the presence of other naturally occurring amino acids, The Bio-
chemical journal 104 (1967) 627–633.
[17] M. Geiszt, J.B. Kopp, P. Varnai, T.L. Leto, Identiﬁcation of renox, an NAD(P)H
oxidase in kidney, Proceedings of the National Academy of Sciences of the
United States of America 97 (2000) 8010–8014.
[18] J.A. Hinson, D.W. Roberts, L.P. James, Mechanisms of acetaminophen-induced
liver necrosis, Handbook of experimental pharmacology (2010) 369–405.
[19] C.A. Hobbs, M.A. Cleves, W. Zhao, S. Melnyk, S.J. James, Congenital heart de-
fects and maternal biomarkers of oxidative stress, The American journal of
clinical nutrition 82 (2005) 598–604.
[20] M.J. Hodgman, A.R. Garrard, A review of acetaminophen poisoning, Critical
care clinics 28 (2012) 499–516.
[21] S.M. Innis, D. Hasman, Evidence of choline depletion and reduced betaine and
dimethylglycine with increased homocysteine in plasma of children with
cystic ﬁbrosis. The, Journal of nutrition 136 (2006) 2226–2231.
[22] H. Jaeschke, M.R. McGill, A. Ramachandran, Oxidant stress, mitochondria, and
cell death mechanisms in drug-induced liver injury: lessons learned from
acetaminophen hepatotoxicity, Drug metabolism reviews 44 (2012) 88–106.
[23] J. Joseph, J. Loscalzo, Methoxistasis: integrating the roles of homocysteine and
folic acid in cardiovascular pathobiology, Nutrients 5 (2013) 3235–3256.
[24] J. Kuroda, T. Ago, S. Matsushima, P. Zhai, M.D. Schneider, J. Sadoshima, NADPH
oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart,
Proceedings of the National Academy of Sciences of the United States of
America 107 (2010) 15565–15570.
[25] B.H. Lauterburg, J.D. Adams, J.R. Mitchell, Hepatic glutathione homeostasis in
the rat: efﬂux accounts for glutathione turnover, Hepatology 4 (1984)
586–590.
[26] J.A. Leopold, J. Loscalzo, Oxidative enzymopathies and vascular disease, Ar-
teriosclerosis, thrombosis, and vascular biology 25 (2005) 1332–1340.
[27] D. Li, L. Pickell, Y. Liu, Q. Wu, J.S. Cohn, R. Rozen, Maternal methylenete-
trahydrofolate reductase deﬁciency and low dietary folate lead to adverse
reproductive outcomes and congenital heart defects in mice, The American
journal of clinical nutrition 82 (2005) 188–195.
T.V.A. Murray et al. / Free Radical Biology and Medicine 89 (2015) 918–930930[28] S.C. Lu, Regulation of glutathione synthesis, Current topics in cellular regula-
tion 36 (2000) 95–116.
[29] J. Lyons, A. Rauh-Pfeiffer, Y.M. Yu, X.M. Lu, D. Zurakowski, R.G. Tompkins, A.
M. Ajami, V.R. Young, L. Castillo, Blood glutathione synthesis rates in healthy
adults receiving a sulfur amino acid-free diet, Proceedings of the National
Academy of Sciences of the United States of America 97 (2000) 5071–5076.
[30] H.L. Martin, P. Teismann, Glutathione–a review on its role and signiﬁcance in
Parkinson’s disease, FASEB journal: ofﬁcial publication of the Federation of
American Societies for Experimental Biology 23 (2009) 3263–3272.
[31] J.M. McCord, The evolution of free radicals and oxidative stress, The American
journal of medicine 108 (2000) 652–659.
[32] D.O. McGregor, W.J. Dellow, M. Lever, P.M. George, R.A. Robson, S.T. Chambers,
Dimethylglycine accumulates in uremia and predicts elevated plasma homo-
cysteine concentrations, Kidney international 59 (2001) 2267–2272.
[33] E. Mosharov, M.R. Cranford, R. Banerjee, The quantitatively important re-
lationship between homocysteine metabolism and glutathione synthesis by
the transsulfuration pathway and its regulation by redox changes, Biochem-
istry 39 (2000) 13005–13011.
[34] T.V. Murray, I. Smyrnias, A.M. Shah, A.C. Brewer, NADPH oxidase 4 regulates
cardiomyocyte differentiation via redox activation of c-Jun protein and the cis-
regulation of GATA-4 gene transcription, The Journal of biological chemistry
288 (2013) 15745–15759.
[35] G. Pare, D.I. Chasman, A.N. Parker, R.R. Zee, A. Malarstig, U. Seedorf, R. Collins,
H. Watkins, A. Hamsten, J.P. Miletich, et al., Novel associations of CPS1, MUT,
NOX4, and DPEP1 with plasma homocysteine in a healthy population: a
genome-wide evaluation of 13 974 participants in the Women’s Genome
Health Study, Circulation Cardiovascular genetics 2 (2009) 142–150.
[36] E.I. Park, T.A. Garrow, Interaction between dietary methionine and methyl
donor intake on rat liver betaine-homocysteine methyltransferase gene ex-
pression and organization of the human gene, The Journal of biological
chemistry 274 (1999) 7816–7824.
[37] L.A. Possamai, M.J. McPhail, A. Quaglia, V. Zingarelli, R.D. Abeles, R. Tidswell,
Z. Puthucheary, J. Rawal, C.J. Karvellas, E.M. Leslie, et al., Character and tem-
poral evolution of apoptosis in acetaminophen-induced acute liver failuren,
Critical care medicine 41 (2013) 2543–2550.
[38] R. Ray, C.E. Murdoch, M. Wang, C.X. Santos, M. Zhang, S. Alom-Ruiz,
N. Anilkumar, A. Ouattara, A.C. Cave, S.J. Walker, et al., Endothelial Nox4
NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo,
Arteriosclerosis, thrombosis, and vascular biology 31 (2011) 1368–1376.
[39] M. Reid, F. Jahoor, Glutathione in disease, Current opinion in clinical nutrition
and metabolic care 4 (2001) 65–71.
[40] K.L. Schalinske, A.L. Smazal, Homocysteine imbalance: a pathological meta-
bolic marker, Adv Nutr 3 (2012) 755–762.
[41] R.V. Sekhar, S.V. McKay, S.G. Patel, A.P. Guthikonda, V.T. Reddy,
A. Balasubramanyam, F. Jahoor, Glutathione synthesis is diminished inpatients with uncontrolled diabetes and restored by dietary supplementation
with cysteine and glycine, Diabetes care 34 (2011) 162–167.
[42] M. Sethuraman, M.E. McComb, T. Heibeck, C.E. Costello, R.A. Cohen, Isotope-
coded afﬁnity tag approach to identify and quantify oxidant-sensitive protein
thiols, Molecular & cellular proteomics: MCP 3 (2004) 273–278.
[43] D. Shah, S. Sah, A. Wanchu, M.X. Wu, A. Bhatnagar, Altered redox state and
apoptosis in the pathogenesis of systemic lupus erythematosus, Im-
munobiology 218 (2013) 620–627.
[44] K. Simpson, C.M. Hogaboam, S.L. Kunkel, D.J. Harrison, C. Bone-Larson, N.
W. Lukacs, Stem cell factor attenuates liver damage in a murine model of
acetaminophen-induced hepatic injury, Laboratory investigation; a journal of
technical methods and pathology 83 (2003) 199–206.
[45] S. Singh, A.R. Khan, A.K. Gupta, Role of glutathione in cancer pathophysiology
and therapeutic interventions, Journal of experimental therapeutics & oncol-
ogy 9 (2012) 303–316.
[46] M.H. Stipanuk, J.E. Dominy, J.I. Lee, R.M. Coloso, Mammalian cysteine meta-
bolism: New insights into regulation of cysteine metabolism, Journal of Nu-
trition 136 (2006) 1652s–1659s.
[47] I. Takac, K. Schroder, L. Zhang, B. Lardy, N. Anilkumar, J.D. Lambeth, A.M. Shah,
F. Morel, R.P. Brandes, The E-loop is involved in hydrogen peroxide formation
by the NADPH oxidase Nox4, The Journal of biological chemistry 286 (2011)
13304–13313.
[48] Y.W. Teng, M.G. Mehedint, T.A. Garrow, S.H. Zeisel, Deletion of betaine-
homocysteine S-methyltransferase in mice perturbs choline and 1-carbon
metabolism, resulting in fatty liver and hepatocellular carcinomas, The Journal
of biological chemistry 286 (2011) 36258–36267.
[49] D.M. Townsend, K.D. Tew, H. Tapiero, The importance of glutathione in human
disease, Biomedicine & pharmacotherapy¼Biomedecine & pharmacotherapie
57 (2003) 145–155.
[50] T.H. Truong, K.S. Carroll, Redox regulation of epidermal growth factor receptor
signaling through cysteine oxidation, Biochemistry 51 (2012) 9954–9965.
[51] V. Vitvitsky, S. Dayal, S. Stabler, Y. Zhou, H. Wang, S.R. Lentz, R. Banerjee,
Perturbations in homocysteine-linked redox homeostasis in a murine model
for hyperhomocysteinemia, American journal of physiology Regulatory, in-
tegrative and comparative physiology 287 (2004) R39–R46.
[52] E.P. Wijekoon, B. Hall, S. Ratnam, M.E. Brosnan, S.H. Zeisel, J.T. Brosnan,
Homocysteine metabolism in ZDF (type 2) diabetic rats, Diabetes 54 (2005)
3245–3251.
[53] G. Wu, Y.Z. Fang, S. Yang, J.R. Lupton, N.D. Turner, Glutathione metabolism and
its implications for health, The Journal of nutrition 134 (2004) 489–492.
[54] M. Zhang, A.C. Brewer, K. Schroder, C.X. Santos, D.J. Grieve, M. Wang,
N. Anilkumar, B. Yu, X. Dong, S.J. Walker, et al., NADPH oxidase-4 mediates
protection against chronic load-induced stress in mouse hearts by enhancing
angiogenesis, Proceedings of the National Academy of Sciences of the United
States of America 107 (2010) 18121–18126.
